Effect of NMU, PYY_3-36, liraglutide or co-treatment with liraglutide and PYY_3-36 on body weight and cumulative energy intake.

<p>(A) Body weight change (% of day 0), (B) Cumulative total energy intake (kJ), (C) cumulative intake of the HPFS diet with 0.5% cholesterol supplement (kJ), and (D) cumulative intake of regular chow (kJ) after 14 days treatment of obese hyperlipidemic hamsters with vehicle (SC, BID) + vehicle (osmotic pump), liraglutide (0.1 mg/kg, SC, BID) + vehicle (osmotic pump), vehicle (SC, BID) + PYY_3-36 (1.0 mg/kg/day, osmotic pump), the co-treatment group liraglutide (0.1 mg/kg, SC, BID) + PYY_3-36 (1.0 mg/kg/day, osmotic pump), or vehicle (SC, BID) + NMU (1.5 mg/kg/day, osmotic pump). Hamsters included in the study were fed a HPFS diet with 0.5% cholesterol supplemented for 12 weeks before initiation of the study. Data are given as mean ± SEM with n = 8/group. Statistical analysis: two-way ANOVA with Bonferronis post hoc test; ^a<i>P</i><0.05 for liraglutide vs. vehicle group, ^b<i>P</i><0.05 for PYY_3-36 vs. vehicle group, ^c<i>P</i><0.05 for PYY_3-36 + liraglutide vs. vehicle group, and ^d<i>P</i><0.05 for NMU vs. vehicle group.